TLSI vs. IRMD, CBLL, BBNX, EMBC, AVNS, BVS, KIDS, RXST, BFLY, and AXGN
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include iRadimed (IRMD), CeriBell (CBLL), Beta Bionics (BBNX), Embecta (EMBC), Avanos Medical (AVNS), Bioventus (BVS), OrthoPediatrics (KIDS), RxSight (RXST), Butterfly Network (BFLY), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.
TriSalus Life Sciences vs. Its Competitors
iRadimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.
In the previous week, iRadimed had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 1 mentions for iRadimed and 0 mentions for TriSalus Life Sciences. iRadimed's average media sentiment score of 1.84 beat TriSalus Life Sciences' score of 0.62 indicating that iRadimed is being referred to more favorably in the media.
92.3% of iRadimed shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 36.8% of iRadimed shares are owned by insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
iRadimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
iRadimed has a net margin of 26.33% compared to TriSalus Life Sciences' net margin of -84.67%. iRadimed's return on equity of 23.28% beat TriSalus Life Sciences' return on equity.
iRadimed has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
iRadimed presently has a consensus target price of $72.00, indicating a potential upside of 16.73%. TriSalus Life Sciences has a consensus target price of $10.75, indicating a potential upside of 113.93%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than iRadimed.
Summary
iRadimed beats TriSalus Life Sciences on 13 of the 17 factors compared between the two stocks.
Get TriSalus Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TriSalus Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:TLSI) was last updated on 7/3/2025 by MarketBeat.com Staff
Free TLSI Stock Alerts